1.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 218, NCT00401011
|
|
2.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CAN-NCIC-IND156, NCIC-156, NCT00053781, IND156
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CAN-NCIC-IND155, NCIC-155, NCT00053794, IND155
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-015, NCI-5983, 5983, NCT00053924
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-014, NCI-5982, NCT00054145, 5982
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: CCC-PHII-44, CHNMC-PHII-44-02166, NCI-5978, 5978, NCT00058214
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1202, NCT00059982, E1202
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-03-C-0157, NCI-5970, NCT00060437
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-12198A, NCI-5938, 5938, NCT00062387
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0276, NCI-5972, NCT00064324, 5972
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 217, NCT00391560
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 212, NCT00375791
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 214, NCT00401388
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Enrolling by invitation
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 211, NCT00398879
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosne 228, NCT00448721
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 210, NCT00455559
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-99-C-0043, NCI-T98-0065, T98-0065, NCT00019656
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WCCC-CO-99906, ASTA-D-21266, NCI-T99-0036, NCT00005794, T99-0036
|
|
19.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 124, NCT00398814
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 127, NCT00415064
|
